TY - JOUR
T1 - Novel agents in the therapy of Hodgkin lymphoma
AU - Ansell, Stephen
PY - 2015
Y1 - 2015
N2 - Hodgkin lymphoma (HL) is a B-cell malignancy that typically has a favorable prognosis when treated with chemotherapy, often in combination with radiation therapy. The prognosis for patients whose disease relapses or is refractory, however, is far less favorable and novel therapies are needed for these patients. The unique cellular composition of HL provides a number of opportunities to target either the malignant Reed-Sternberg cell or the inflammatory tumor microenvironment. Antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints, have all demonstrated activity in HL. Current and future trials are exploring the use of these agents in combination with each other and with standard chemotherapy.
AB - Hodgkin lymphoma (HL) is a B-cell malignancy that typically has a favorable prognosis when treated with chemotherapy, often in combination with radiation therapy. The prognosis for patients whose disease relapses or is refractory, however, is far less favorable and novel therapies are needed for these patients. The unique cellular composition of HL provides a number of opportunities to target either the malignant Reed-Sternberg cell or the inflammatory tumor microenvironment. Antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints, have all demonstrated activity in HL. Current and future trials are exploring the use of these agents in combination with each other and with standard chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84957963896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84957963896&partnerID=8YFLogxK
U2 - 10.14694/EdBook_AM.2015.35.e479
DO - 10.14694/EdBook_AM.2015.35.e479
M3 - Review article
C2 - 25993212
AN - SCOPUS:84957963896
SN - 1548-8756
SP - e479-e482
JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
ER -